MedTrace Logo

Study in Participants With Acute Migraines Headaches

NCT00804973 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2020-05-19

Study results available
· View outcomes & findings →

Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.

Conditions

  • Migraine Headache

Interventions

DRUG

LY2590443

200 milligrams (mg) as four 50-mg capsules, oral, once

DRUG

Placebo injection

saline solution, injection, once

DRUG

Sumatriptan

6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once

DRUG

Placebo capsule

4 capsules, once

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00804973 on ClinicalTrials.gov